FDA Panel Recommends Tysabri

An FDA panel has recommended that the risky and controversial MS drug Tysabri be returned to the market.  The panel argued that the decision to use the drug should be made by the doctor and the patient, in spite of evidence that the drug causes a deadly brain disease.  If the FDA accepts the panel’s recommendation, it would be only the second time a drug was returned to the market after having been removed for safety reasons.